249 results about "Estrogen" patented technology

Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

The invention provides a method for breeding all-male hybrid pelteobagrus fulvidraco through hybridization of double super-male populations, which comprises the following steps: S1, respectively constructing super-male maintenance lines of pelteobagrus fulvidraco and pelteobagrus vachelli by utilizing a sex reversal technology and a sex molecular marker; s2, carrying out artificial propagation on the maintenance line, and propagating the super male fish in batches; s3, partially replacing estrogen with an androgen antagonist for the propagated supermale fish, and synergistically inducing the supermale fish to obtain superfemale fish; s4, performing specific nutrient enrichment cultivation on the super female fish and the super male parent fish; and S5, carrying out reciprocal cross artificial propagation on the super-female fish and the super-male fish between the two super-male groups to obtain a heterozygous super-male group, namely commercial fry of the all-male hybrid pelteobagrus fulvidraco. According to the technical scheme, super-female fishes can be efficiently induced in batches, high-density breeding of parent fishes is achieved, and the effect and efficiency of artificial breeding are remarkably improved; the bred hybrid all-realgar catfish is high in individual uniformity, the growth speed is increased by 20%, and the male rate reaches 100%.

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The invention provides a multi-walled carbon nanotube paste electrode based on gold nanoparticles and C60 modification as well as a preparation method and application thereof, and belongs to the technical field of electrochemical sensors. The preparation method comprises the following steps: firstly, modifying fullerene C60 on the surface of a carbon nanotube paste electrode (MWCNTPE) to form C60 / MWCNTPE, then loading gold nanoparticles on the surface of the C60 / MWCNTPE, and finally constructing the AuNPs / C60 / MWCNTPE composite electrode. The prepared composite electrode is used for environmental estrogen detection, especially for simultaneous detection of hydroquinone, catechol and bisphenol A. The method has the advantages of high sensitivity and low detection limit, can solve the problem that hydroquinone and catechol isomeride are difficult to separate through the detection capability, has the advantages of simplicity and convenience in operation and low cost, and has good practical applicability, stability and reproducibility.

Disclosed are devices and methods for providing local administration of a sex hormone composition in a mammalian body to promote bone remodeling. The device includes an implantable structure configured for placement at a target intraosseous and / or periosteal site in the mammalian body and an effective amount of a sex hormone composition associated with the implantable structure. The sex hormone composition comprises both an estrogen and an androgen.

The present disclosure provides a method of treating estrogen receptor-positive (ER+) breast cancer, comprising the combined administration of therapeutically effective amounts of a KAT6A / B inhibitor and a Menin inhibitor to a patient in need thereof.

The invention relates to the technical field of medical informatics, in particular to an intelligent endometrial receptivity evaluation system based on multi-modal fusion. The system comprises a memory and a processor, and the processor executes a computer program stored in the memory so as to realize the following steps: acquiring endometrial thickness, estrogen content, luteal hormone content and pulse index of a reference person and a person to be evaluated; determining the intimal change stability according to the endometrial thickness increase characteristics of the reference person; according to the fluctuation condition of the estrogen content of the reference personnel, the decrease condition of the estrogen content detected in two adjacent times and the change condition of the luteal hormone content, determining the category of the to-be-evaluated personnel; and determining the creep over-frequency expression degree by combining the decreasing condition of the pulse index of the to-be-evaluated person and the uterine contraction condition so as to obtain a comprehensive index. According to the method, the data of different dimensions of the endometrium of the to-be-evaluated person is synthesized to obtain the comprehensive index, and reference data is provided for subsequent evaluation of a doctor.

Described herein are pinoxifene compositions comprising novel compounds and methods of use thereof. Methods of synthesizing the compositions are described herein. The odoxifene compositions described herein may exhibit aromatase inhibitory activity or estrogen receptor activity. The odoxifene compositions described herein can be used to treat a condition, such as cancer, in a subject.

The invention relates to the field of biological medicine, and discloses application of ergothioneine in preparation of a medicine for preventing and / or treating osteoporosis. The invention discloses a new mechanism of the ergothioneine for improving the osteoporosis by regulating and controlling the NF-kB / NFATc1 signal channel and reducing oxidative stress and inflammatory response for the first time, and provides a brand new thought for developing safe and effective anti-osteoporosis medicines. The discovery that the ergothioneine improves bone mass loss related to estrogen decline provides a new solution for lack of osteoporosis treatment means at present, and opens up a new way for application of natural products in bone metabolic diseases.

The present invention relates to a compound of the formula (i) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a —COR4 group, (2) a —BOR5OR6 group, (3) a —X—Z group, (4) a (C1-C6)alkyl group or a (C1-C6)alkenyl group, (5) a —X—S(O)n(R7)p(R8)q group, (6) a halogen atom, a —NH2 group or a —CN group, (7) a —O—R11 group, (8) a —NH—COR9 group, (9) a —C(═NH)NHOH group, (10) a —NH—C(NH)—R9′ group, or (11) a —NHCOCOOR12 group or a —NHCOCONR12′R12″ group, X represents a bond, a —NH— group, a —CONH— group or a —CO— group, Z represents a 4 or 5-membered cycloalkyl, a 4 or 5-membered heterocylcloalkyl group, a 4 or 5-membered heteroaryl group or a phenyl group or a pharmaceutically acceptable salt thereof. The present invention further relates to a medicament comprising said compound of formula (I) and to said compound of formula (I) for use as an inhibitor and degrader of estrogen receptors.

The invention relates to the technical field of functional drinks, in particular to a polypeptide synergistically strengthened cubilose collagen composite drink with a breast enlarging function and a preparation method of the polypeptide synergistically strengthened cubilose collagen composite drink. The drink contains fish collagen tripeptide, elastin peptide, cubilose peptide, pueraria mirifica isoflavone, red clover isoflavone and saffron crocus extract. A lipidosome delivery system is adopted to entrap polypeptide to form a nano-scale compound, nano-emulsion entraps phytoestrogen, and berry polyphenol and lipidosome-polypeptide form a stable ternary compound. Through the multi-way synergistic effect that phytoestrogen activates a mammary gland estrogen receptor, polypeptide promotes connective tissue collagen synthesis and cubilose peptide activates a growth factor signal, mammary gland development is remarkably promoted, the breast enlarging effect is achieved, the bioavailability reaches 85% or above, and the retention rate of active ingredients stored at normal temperature for 24 months is larger than 90%.

The invention provides a novel application of a raspberry extract. It is found through tests that any one of isoquercitrin, ellagic acid, vanillic acid, oleanolic acid, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, tiliroside, tormentic acid and raspberry extract can remarkably improve the activity of the human ovarian granular cells or remarkably improve the oxidative stress level, and the activity of the human ovarian granular cells can be remarkably improved. According to the present invention, the ovarian function can be effectively protected by the eight components, the ovarian function can be effectively protected by the eight components, or the mitochondrial membrane potential level can be significantly regulated and controlled, or the estrogen level in the microenvironment can be effectively maintained, such that the ovarian function can be effectively protected by the eight components, and the raspberry extract containing the eight components. The invention provides a new choice for ovarian function protection products, and also provides a new application for the substances.

This invention discloses a yam oxylipoic acid compound with aromatase inhibitory activity, its application, and analytical identification methods, belonging to the field of medicinal chemistry. The yam oxylipoic acid compound is (Z)-9-ethoxy-6,10-dihydroxyoctadec-7-enoic acid, a novel compound. This compound can significantly inhibit aromatase activity and possesses the ability to inhibit excessive estrogen production, thus showing promising application prospects and value in diseases related to estrogen imbalance regulation.

Disclosed herein are methods for treating cancer comprising administering to a subject a daily dose of Compound A or a pharmaceutically acceptable salt thereof in combination with an Akt inhibitor.

The invention relates to an estrogen receptor alpha and fibroblast activating protein dual-targeting near-infrared fluorescent probe as well as a preparation method and medical application thereof. Specifically, the probe can be used as a fluorescence probe for developing cells co-expressing the estrogen receptor alpha and the fibroblast activating protein, and can also be used as a near-infrared fluorescence imaging probe for diagnosing benign / malignant lesions such as nodules / tumors co-expressing the estrogen receptor alpha and the fibroblast activating protein. The fluorescent probe can also be applied to research on related biological events in cells for co-expressing the estrogen receptor alpha and the fibroblast activating protein, and particularly can be applied to fluorescent navigation in tumor resection operations for co-expressing the estrogen receptor alpha and the fibroblast activating protein; particularly, the composition can be applied to the synergistic treatment of an anti-estrogen therapy and a photodynamic therapy on a diseased region which co-expresses the estrogen receptor alpha and the fibroblast activating protein.

A compound represented by formula (I) or a stereoisomer, tautomer or pharmaceutical salt thereof, and its use in the preparation of a medicament to prevent and / or treat estrogen receptor (ER) related diseases or disorders.

The present disclosure relates to novel chroman derivatives having estrogen receptor degrading activity and uses thereof. In particular, the present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in the prevention and treatment of cancer and related diseases and conditions.

The application provides an application of Lipofermata in preparation of a product for preventing and treating osteoporosis. The pharmacological experiment of the application shows that Lipofermata can significantly prevent and treat and improve the reduction of bone mass caused by estrogen reduction, and shows that Lipofermata has the effect of preventing and treating osteoporosis, and therefore can be used for preventing and treating osteoporosis. The application not only provides a new therapeutic use of Lipofermata, but also provides a new drug for preventing and treating osteoporosis.

The application relates to the field of animal immunization castration vaccines, in particular to a protein, a nucleic acid, an expression vector, a castration vaccine, a method and application. The protein is shown as SEQ ID NO: 1. The nucleic acid is shown as SEQ ID NO: 2. The expression vector comprises the nucleic acid. The castration vaccine takes the protein, the nucleic acid or the expression vector as an effective component. The method comprises the steps of preparing the nucleic acid and / or the expression vector. The application comprises the preparation of the castration vaccine. The protein, the nucleic acid, the expression vector and / or the castration vaccine can produce an immune response in mice, reduce the testosterone and estrogen levels in mice and produce obvious trend effects.

This invention belongs to the field of pharmaceutical technology, specifically relating to ligand modulators targeting the estrogen-related receptor ERRγ and their uses. In a first aspect, this invention provides the use of small molecule compounds in the preparation of ligand modulators targeting the estrogen-related receptor ERRγ, said small molecule compounds being as shown in formula (I). In a second aspect, this invention also provides the use of the small molecule compounds described in the first aspect in the preparation of drugs for the prevention or treatment of ERRγ-related diseases. This invention provides a series of small molecule compounds targeting the estrogen-related receptor ERRγ as its ligand modulators, solving the problem of low drugability of ERRγ and providing more options for the development of related drugs, thus showing good prospects for development and utilization.

Disclosed are 4-hydroxylphenyl substituted carbocycles and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with ER activity, such as proliferative diseases and disorders and / or psychiatric diseases or disorders.

The invention relates to the technical field of traditional Chinese medicines, in particular to anti-osteoporosis processed isinglass as well as preparation and application thereof. According to the prepared isinglass provided by the invention, the component M is less than or equal to 5kDa, and the proportion is 63.71%, so that the intestinal absorption efficiency and the bioavailability can be remarkably improved. The invention also provides an application of the processed isinglass in preparation of medicines. The medicines can be used for treating and / or preventing osteoporosis caused by estrogen deficiency, intestinal flora imbalance caused by estrogen deficiency or bone diseases caused by estrogen deficiency. Compared with traditional donkey-hide gelatin, the prepared isinglass is better in molecular weight distribution and richer in Maillard reaction products; compared with swim bladder collagen which is not processed by the preparation method disclosed by the invention, the processed swim bladder collagen disclosed by the invention generates active ingredients such as melanoidins through a Maillard reaction, and the active ingredients are cooperated with amino acids, so that the limitation of traditional glues in anti-osteoporosis application is broken through, and a scientific basis is provided for development of functional bone health products.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

The invention relates to the technical field of medicines, in particular to application of osthole in preparation of a medicine for protecting cognitive function impairment caused by down-regulation of an estrogen receptor. The OST has an improvement effect on the learning and memory ability and pathological damage of 6-month-old female peripheral ERs down-regulated mice and ER alpha- / -mouse models. The mechanism of the OST for improving learning and memory may be related to improvement of neuroplasticity, inhibition of nerve apoptosis and enhancement of neurotransmitter by regulating and controlling an estrogen-cholinergic system by the OST. The OST has a better intervention effect on a 6-month-old female ER alpha- / -mouse model, and possibly is a kidney-tonifying medicine which acts on a related target spot of a peripheral target organ so as to participate in regulation of a cognitive function of a central system.

The present application relates to treating and / or preventing breast cancer, including locally advanced or metastatic, ER+, HER2- breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof.

Novel selective estrogen receptor degraders (SERDs) according to the following formula and pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof: wherein R is selected from the group consisting of

The invention provides a novel estrogen receptor protein degradation targeting chimera compound and application of the novel estrogen receptor protein degradation targeting chimera compound in medicine. The compound provided by the invention can be used as an estrogen receptor degradation agent for treating estrogen dependent diseases.

The application discloses application of microRNA-32-5p in preparation of a medicine for preventing and treating osteoporosis, and a medicine composition taking microRNA-32-5p as an active ingredient. It is proved through experiments that knocking out the microRNA-32-5p gene significantly aggravates osteoporosis induced by estrogen deficiency; the microRNA-32-5p plays a bone protection role by promoting osteogenic differentiation of bone marrow mesenchymal stem cells. Therefore, the microRNA-32-5p can be applied to prevention and treatment of osteoporosis as a microRNA medicine.